Candidate prognostic markers in breast cancer: focus on extracellular proteases and their inhibitors

References

• OverallCMBlobelCPIn search of partners: linking extracellular proteases to substratesNat Rev Mol Cell Biol20078324525717299501
   PubMed Web of Science ®Google Scholar
• YadavLPuriNRastogiVSatputePAhmadRKaurGMatrix metalloproteinases and cancer – roles in threat and therapyAsian Pac J Cancer Prev20141531085109124606423
   PubMedGoogle Scholar
• KoblinskiJEAhramMSloaneBFUnraveling the role of proteases in cancerClin Chim Acta2000291211313510675719
   PubMed Web of Science ®Google Scholar
• WangXWilsonMJSlatonJWSinhaAAEwingSLPeiDIncreased aggressiveness of human prostate PC-3 tumor cells expressing cell surface localized membrane type-1 matrix metalloproteinase (MT1-MMP)J Androl200930325927419136391
   PubMedGoogle Scholar
• Chimal-RamírezGKEspinoza-SánchezNAUtrera-BarillasDMMP1, MMP9, and COX2 expressions in promonocytes are induced by breast cancer cells and correlate with collagen degradation, transformation-like morphological changes in MCF-10A acini, and tumor aggressivenessBiomed Res Int2013201327950523762835
   PubMed Web of Science ®Google Scholar
• SunJMatrix metalloproteinases and tissue inhibitor of metalloproteinases are essential for the inflammatory response in cancer cellsJ Signal Transduct2010201098513221152266
   PubMedGoogle Scholar
• CurtisCShahSPChinSFThe genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsNature2012486740334635222522925
   PubMed Web of Science ®Google Scholar
• FrantzCStewartKMWeaverVMThe extracellular matrix at a glanceJ Cell Sci2010123Pt 244195420021123617
   PubMed Web of Science ®Google Scholar
• KimSHTurnbullJGuimondSExtracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptorJ Endocrinol2011209213915121307119
   PubMed Web of Science ®Google Scholar
• BosmanFTStamenkovicIFunctional structure and composition of the extracellular matrixJ Pathol2003200442342812845610
   PubMed Web of Science ®Google Scholar
• Di LulloGASweeneySMKorkkoJAla-KokkoLSan AntonioJDMapping the ligand-binding sites and disease-associated mutations on the most abundant protein in the human, type I collagenJ Biol Chem200227764223423111704682
   PubMed Web of Science ®Google Scholar
• SalamASimpsonMAStoneKLNext generation diagnostics of heritable connective tissue disordersMatrix Biol201433354023896220
   PubMed Web of Science ®Google Scholar
• TanjoreHKalluriRThe role of type IV collagen and basement membranes in cancer progression and metastasisAm J Pathol2006168371571716507886
   PubMed Web of Science ®Google Scholar
• PolyakKMolecular markers for the diagnosis and management of ductal carcinoma in situJ Natl Cancer Inst Monogr201020104121021320956832
   PubMedGoogle Scholar
• SchmidtSFriedlPInterstitial cell migration: integrin-dependent and alternative adhesion mechanismsCell Tissue Res20103391839219921267
   PubMed Web of Science ®Google Scholar
• CoxTRErlerJTRemodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancerDis Model Mech20114216517821324931
   PubMed Web of Science ®Google Scholar
• SchaeferLSchaeferRMProteoglycans: from structural compounds to signaling moleculesCell Tissue Res2010339123724619513755
   PubMed Web of Science ®Google Scholar
• LeonovaEIGalzitskayaOVStructure and functions of syndecans in vertebratesBiochemistry (Mosc)201378101071108524237141
   PubMed Web of Science ®Google Scholar
• BarbouriDAfratisNGialeliCVyniosDHTheocharisADKaramanosNKSyndecans as modulators and potential pharmacological targets in cancer progressionFront Oncol20144424551591
   PubMedGoogle Scholar
• LuPWeaverVMWerbZThe extracellular matrix: a dynamic niche in cancer progressionJ Cell Biol2012196439540622351925
   PubMed Web of Science ®Google Scholar
• LamyPJMartinPMRomieuGJacotWRe: clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic reviewJ Natl Cancer Inst2013105214923243205
   PubMedGoogle Scholar
• TessariAPalmieriDDi CosimoSOverview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patientsPharmgenomics Pers Med2013711924403841
   PubMedGoogle Scholar
• TurnerNPestrinMGalardiFDe LucaFMalorniLDi LeoACan biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer?Cancers (Basel)20146268470724670368
   PubMed Web of Science ®Google Scholar
• MulraneLKlingerRMcGeeSFGallagherWMO’ConnorDPmicroRNAs: a new class of breast cancer biomarkersExpert Rev Mol Diagn201414334736324649821
   PubMed Web of Science ®Google Scholar
• AndresSAEdwardsABWittliffJLExpression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevanceJ Clin Lab Anal20122629310322467324
   PubMed Web of Science ®Google Scholar
• JänickeFPrechtlAThomssenCGerman N0 Study GroupRandomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1J Natl Cancer Inst2001931291392011416112
   PubMedGoogle Scholar
• LookMPvan PuttenWLDuffyMJPooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patientsJ Natl Cancer Inst200294211612811792750
   PubMedGoogle Scholar
• TangLHanXThe urokinase plasminogen activator system in breast cancer invasion and metastasisBiomed Pharmacother201367217918223201006
   PubMed Web of Science ®Google Scholar
• HarbeckNSotlarKWuerstleinRDoisneau-SixouSMolecular and protein markers for clinical decision making in breast cancer: today and tomorrowCancer Treat Rev201440343444424138841
   PubMed Web of Science ®Google Scholar
• McMahonBKwaanHCThe plasminogen activator system and cancerPathophysiol Haemost Thromb2008363–418419419176991
   PubMedGoogle Scholar
• MekkawyAHPourgholamiMHMorrisDLInvolvement of urokinase-type plasminogen activator system in cancer: an overviewMed Res Rev Epub2182014
   Web of Science ®Google Scholar
• UrbanPVuaroqueauxVLabuhnMIncreased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancerJ Clin Oncol200624264245425316963728
   PubMed Web of Science ®Google Scholar
• BinderBRMihalyJThe plasminogen activator inhibitor “paradox” in cancerImmunol Lett2008118211612418495253
   PubMed Web of Science ®Google Scholar
• DuffyMJThe urokinase plasminogen activator system: role in malignancyCurr Pharm Des2004101394914754404
   PubMed Web of Science ®Google Scholar
• CeramiEGaoJDogrusozUThe cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics dataCancer Discov20122540140422588877
   PubMed Web of Science ®Google Scholar
• GaoJAksoyBADogrusozUIntegrative analysis of complex cancer genomics and clinical profiles using the cBioPortalSci Signal20136269pl123550210
   PubMed Web of Science ®Google Scholar
• LumachiFLuisettoGBassoSMBassoUBrunelloACamozziVEndocrine therapy of breast cancerCurr Med Chem201118451352221143113
   PubMed Web of Science ®Google Scholar
• SchiavonGSmithIEEndocrine therapy for advanced/metastatic breast cancerHematol Oncol Clin North Am2013274715736viii23915741
   PubMed Web of Science ®Google Scholar
• Meijer-van GelderMELookMPPetersHAUrokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent diseaseCancer Res200464134563456815231667
   PubMed Web of Science ®Google Scholar
• WoessnerJFJrMMPs and TIMPs – an historical perspectiveMol Biotechnol2002221334912353913
   PubMed Web of Science ®Google Scholar
• GibsonDJSchultzGSMolecular wound assessments: matrix metalloproteinasesAdv Wound Care (New Rochelle)201321182324527319
   PubMedGoogle Scholar
• JavaidMAAbdallahMNAhmedASSheikhZMatrix metalloproteinases and their pathological upregulation in multiple sclerosis: an overviewActa Neurol Belg2013113438139024002649
   PubMed Web of Science ®Google Scholar
• VisseRNagaseHMatrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistryCirc Res200392882783912730128
   PubMed Web of Science ®Google Scholar
• KleinTBischoffRPhysiology and pathophysiology of matrix metalloproteasesAmino Acids201141227129020640864
   PubMed Web of Science ®Google Scholar
• KulićADedić PlavetićNVrbanecJSirotković-SkerlevMLow serum MMP-1 in breast cancer: a negative prognostic factor?Biomarkers201217541642122515421
   PubMed Web of Science ®Google Scholar
• PuzovicVBrcicIRanogajecIJakic-RazumovicJPrognostic values of ETS-1, MMP-2 and MMP-9 expression and co-expression in breast cancer patientsNeoplasma Epub3202014
   Web of Science ®Google Scholar
• Fernandez-GarciaBEiróNMarínLExpression and prognostic significance of fibronectin and matrix metalloproteases in breast cancer metastasisHistopathology201464451252224117661
   PubMed Web of Science ®Google Scholar
• van der JagtMFWobbesTStrobbeLJSweepFCSpanPNMetalloproteinases and their regulators in colorectal cancerJ Surg Oncol2010101325926920039272
   PubMed Web of Science ®Google Scholar
• de la PeñaSSampieriCLLeón-CórdobaKMatrix metalloproteases as molecular markers in gastric cancerMed Clin (Barc)20101343123126 Spanish19944435
   PubMed Web of Science ®Google Scholar
• RydlovaMHolubecLJrLudvikovaMJrBiological activity and clinical implications of the matrix metalloproteinasesAnticancer Res2008282B1389139718505085
   PubMed Web of Science ®Google Scholar
• ŁukaszewiczMMroczkoBSzmitkowskiMThe role of metalloproteinases and their inhibitors in pancreatic cancerPostepy Hig Med Dosw (Online)20086214114718414340
   PubMedGoogle Scholar
• LibraMScalisiAVellaNUterine cervical carcinoma: role of matrix metalloproteinases (review)Int J Oncol200934489790319287946
   PubMed Web of Science ®Google Scholar
• LimSCExpression of c-erbB receptors, MMPs and VEGF in head and neck squamous cell carcinomaBiomed Pharmacother200559Suppl 2S366S36916507411
   PubMed Web of Science ®Google Scholar
• McGowanPMDuffyMJMatrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published databaseAnn Oncol20081991566157218503039
   PubMed Web of Science ®Google Scholar
• ChengCWYuJCWangHWThe clinical implications of MMP-11 and CK-20 expression in human breast cancerClin Chim Acta20104113–423424119914229
   PubMed Web of Science ®Google Scholar
• TanJBuacheEAlpyFStromal matrix metalloproteinase-11 is involved in the mammary gland postnatal developmentOncogene Epub10212013
   Web of Science ®Google Scholar
• TakeuchiTAdachiYNagayamaTFurihataMMatrix metalloproteinase-11 overexpressed in lobular carcinoma cells of the breast promotes anoikis resistanceVirchows Arch2011459329129721773755
   PubMed Web of Science ®Google Scholar
• SongJSuHZhouYYGuoLLPrognostic value of matrix metalloproteinase 9 expression in breast cancer patients: a meta-analysisAsian Pac J Cancer Prev20131431615162123679245
   PubMedGoogle Scholar
• Talvensaari-MattilaAPääkköPTurpeenniemi-HujanenTMatrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinomaBr J Cancer20038971270127514520459
   PubMed Web of Science ®Google Scholar
• JezierskaAMotylTMatrix metalloproteinase-2 involvement in breast cancer progression: a mini-reviewMed Sci Monit2009152RA32RA4019182722
   PubMed Web of Science ®Google Scholar
• TortorellaMDMalfaitFBarveRAShiehHSMalfaitAMA review of the ADAMTS family, pharmaceutical targets of the futureCurr Pharm Des200915202359237419601837
   PubMed Web of Science ®Google Scholar
• WeberSSaftigPEctodomain shedding and ADAMs in developmentDevelopment2012139203693370922991436
   PubMed Web of Science ®Google Scholar
• MochizukiSOkadaYADAMs in cancer cell proliferation and progressionCancer Sci200798562162817355265
   PubMed Web of Science ®Google Scholar
• PollheimerJFockVKnöflerMReview: the ADAM metalloproteinases – novel regulators of trophoblast invasion?Placenta201435SupplS57S6324231445
   PubMed Web of Science ®Google Scholar
• FlanneryCRMMPs and ADAMTSs: functional studiesFront Biosci20061154456916146752
   PubMed Web of Science ®Google Scholar
• DuffyMJMulloolyMO’DonovanNThe ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?Clin Proteomics201181921906355
   PubMedGoogle Scholar
• GoozMADAM-17: the enzyme that does it allCrit Rev Biochem Mol Biol201045214616920184396
   PubMed Web of Science ®Google Scholar
• McGowanPMRyanBMHillADMcDermottEO’HigginsNDuffyMJADAM-17 expression in breast cancer correlates with variables of tumor progressionClin Cancer Res20071382335234317438092
   PubMed Web of Science ®Google Scholar
• KennyPABissellMJTargeting TACE-dependent EGFR ligand shedding in breast cancerJ Clin Invest2007117233734517218988
   PubMed Web of Science ®Google Scholar
• McGowanPMMcKiernanEBolsterFADAM-17 predicts adverse outcome in patients with breast cancerAnn Oncol20081961075108118238782
   PubMed Web of Science ®Google Scholar
• BolgerJCYoungLSADAM22 as a prognostic and therapeutic drug target in the treatment of endocrine-resistant breast cancerVitam Horm20139330732123810013
   PubMed Web of Science ®Google Scholar
• RomagnoliMMinevaNDPolmearMADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasisEMBO Mol Med20146227829424375628
   PubMed Web of Science ®Google Scholar
• MurphyGTissue inhibitors of metalloproteinasesGenome Biol2011121123322078297
   PubMed Web of Science ®Google Scholar
• Stetler-StevensonWGTissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activitiesSci Signal2008127re618612141
   PubMed Web of Science ®Google Scholar
• SeoDWLiHGuedezLTIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanismCell2003114217118012887919
   PubMed Web of Science ®Google Scholar
• WuZSWuQYangJHPrognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancerInt J Cancer200812292050205618172859
   PubMed Web of Science ®Google Scholar
• SchrohlASHolten-AndersenMNPetersHATumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancerClin Cancer Res20041072289229815073104
   PubMed Web of Science ®Google Scholar
• ToricelliMMeloFHPeresGBSilvaDCJasiulionisMGTimp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylationMol Cancer2013122223522389
   PubMed Web of Science ®Google Scholar
• OhJSeoDWDiazTTissue inhibitors of metalloproteinase 2 inhibits endothelial cell migration through increased expression of RECKCancer Res200464249062906915604273
   PubMed Web of Science ®Google Scholar
• RemacleAMcCarthyKNoëlAHigh levels of TIMP-2 correlate with adverse prognosis in breast cancerInt J Cancer200089211812110756061
   PubMed Web of Science ®Google Scholar
• MylonaEMagkouCGiannopoulouIExpression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: relation to tumor phenotype and clinical outcomeBreast Cancer Res200685R5717032447
   PubMed Web of Science ®Google Scholar
• SpanPNLindbergRLMandersPTissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy successJ Pathol2004202439540215095266
   PubMed Web of Science ®Google Scholar
• WangMLiuYEGreeneJInhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4Oncogene19971423276727749190892
   PubMed Web of Science ®Google Scholar
• LissMSreedharNKeshgegianATissue inhibitor of metalloproteinase-4 is elevated in early-stage breast cancers with accelerated progression and poor clinical courseAm J Pathol2009175394094619700750
   PubMed Web of Science ®Google Scholar
• OhJTakahashiRKondoSThe membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesisCell2001107678980011747814
   PubMed Web of Science ®Google Scholar
• ReisSTPontes-JuniorJAntunesAAmiR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancerBMC Urol2012121422642976
   PubMed Web of Science ®Google Scholar
• ChangCKHungWCChangHCThe Kazal motifs of RECK protein inhibit MMP-9 secretion and activity and reduce metastasis of lung cancer cells in vitro and in vivoJ Cell Mol Med2008126B2781278918194466
   PubMed Web of Science ®Google Scholar
• SpanPNSweepCGMandersPBeexLVLeppertDLindbergRLMatrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: a prognostic marker for good clinical outcome in human breast carcinomaCancer200397112710271512767082
   PubMed Web of Science ®Google Scholar
• ZhangYChengSZhangGLow expression of RECK indicates a shorter survival for patients with invasive breast cancerCancer Sci201210361084108922404079
   PubMed Web of Science ®Google Scholar
• HillVKRickettsCBiecheIGenome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicityCancer Res20117182988299921363912
   PubMed Web of Science ®Google Scholar
• WalshLARoyDMReyngoldMRECK controls breast cancer metastasis by modulating a convergent, STAT3-dependent neoangiogenic switchOncogene Epub2014616
   Web of Science ®Google Scholar
• American Cancer SocietyCancer Facts and FiguresAtlanta, GAThe Societyv
   Google Scholar
• WeigelMTDowsettMCurrent and emerging biomarkers in breast cancer: prognosis and predictionEndocr Relat Cancer2010174R245R26220647302
   PubMed Web of Science ®Google Scholar
• OverallCMLópez-OtínCStrategies for MMP inhibition in cancer: innovations for the post-trial eraNat Rev Cancer20022965767212209155
   PubMed Web of Science ®Google Scholar
• CoussensLMFingletonBMatrisianLMMatrix metalloproteinase inhibitors and cancer: trials and tribulationsScience200229555642387239211923519
   PubMed Web of Science ®Google Scholar
• VartakDGGemeinhartRAMatrix metalloproteases: underutilized targets for drug deliveryJ Drug Target200715112017365270
   PubMed Web of Science ®Google Scholar
• LeighlNBPaz-AresLDouillardJYRandomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18J Clin Oncol200523122831283915837997
   PubMed Web of Science ®Google Scholar
• BernardoMMBrownSLiZHFridmanRMobasherySDesign, synthesis, and characterization of potent, slow-binding inhibitors that are selective for gelatinasesJ Biol Chem200227713112011120711790786
   PubMed Web of Science ®Google Scholar
• LevittNCEskensFAO’ByrneKJPhase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancerClin Cancer Res2001771912192211448904
   PubMed Web of Science ®Google Scholar
• GriffinMOFricovskyECeballosGVillarrealFTetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literatureAm J Physiol Cell Physiol20102993C539C54820592239
   PubMed Web of Science ®Google Scholar
• HirteHVergoteIBJeffreyJRA phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group StudyGynecol Oncol2006102230030816442153
   PubMed Web of Science ®Google Scholar
• MacaulayVMO’ByrneKJSaundersMPPhase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusionsClin Cancer Res19995351352010100701
   PubMed Web of Science ®Google Scholar
• LuCLeeJJKomakiRChemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trialJ Natl Cancer Inst20101021285986520505152
   PubMed Web of Science ®Google Scholar
• ChuQSForouzeshBSyedSA phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomasInvest New Drugs200725435936717237909
   PubMedGoogle Scholar
• BissettDO’ByrneKJvon PawelJPhase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancerJ Clin Oncol200523484284915681529
   PubMed Web of Science ®Google Scholar
• KhanSAChattertonRTMichelNSoy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trialCancer Prev Res (Phila)20125230931922307566
   PubMed Web of Science ®Google Scholar
• MillerKDGradisharWSchuchterLA randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancerAnn Oncol20021381220122412181245
   PubMed Web of Science ®Google Scholar
• HundhausenCMisztelaDBerkhoutTAThe disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesionBlood200310241186119512714508
   PubMed Web of Science ®Google Scholar
• McGowanPMMulloolyMCaiazzaFADAM-17: a novel therapeutic target for triple negative breast cancerAnn Oncol201324236236922967992
   PubMed Web of Science ®Google Scholar
• JohTKataokaHTanidaSHelicobacter pylori-stimulated interleukin-8 (IL-8) promotes cell proliferation through transactivation of epidermal growth factor receptor (EGFR) by disintegrin and metalloproteinase (ADAM) activationDig Dis Sci200550112081208916240219
   PubMed Web of Science ®Google Scholar
• ZhouBBPeytonMHeBTargeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancerCancer Cell2006101395016843264
   PubMed Web of Science ®Google Scholar
• WittersLScherlePFriedmanSSynergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitorCancer Res200868177083708918757423
   PubMed Web of Science ®Google Scholar
• HeinemannVEbertMPLaubenderRPBevanPMalaCBoeckSPhase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancerBr J Cancer2013108476677023412098
   PubMed Web of Science ®Google Scholar
• StillfriedGESaundersDNRansonMPlasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activityBreast Cancer Res200791R1417257442
   PubMed Web of Science ®Google Scholar